Skip to main content
. 2012 Mar 26;119(20):4608–4613. doi: 10.1182/blood-2011-12-395715

Table 4.

Response among evaluable patients and selected subgroups

Patients (n = 25), n (%)
Response
    VGPR 6 (24)
    PR 7 (28)
    MR 6 (24)
    Stable disease 4 (16)
    Progressive disease 2 (8)
VGPR and PR in selected subgroups 13
    Previous use of thalidomide only 4 (31)
    Previous use of lenalidomide only 5 (38)
    Previous use of thalidomide + lenalidomide 3 (23)
    No previous use of thalidomide or lenalidomide 1 (8)

VGPR indicates very good partial remission; PR, partial remission; and MR, minor remission.